Key result
This protocol outlines a randomized trial evaluating the cardiovascular, renal, and gastrointestinal effects of incretin-based therapies versus placebo in 60 patients with type 2 diabetes.
Why the study?
Do incretin-based therapies (exenatide, liraglutide, sitagliptin) affect cardiovascular, renal, and gastrointestinal surrogate markers in patients with type 2 diabetes?
Population
60 patients with type 2 diabetes
Comparison
Acute intervention: intravenous administration… vs Matching placebos (acute and prolonged)
Design
Other, randomised, double-blind
Follow-up
12 weeks
Authors
Loading...
This protocol outlines a mechanistic trial to investigate the acute and 12-week cardiovascular, renal, and gastrointestinal effects of incretin-based therapies in patients with type 2 diabetes.
RCT (n=60)
double-blind
randomised
Do incretin-based therapies (exenatide, liraglutide, sitagliptin) affect cardiovascular, renal, and gastrointestinal surrogate markers in patients with type 2 diabetes?
This protocol outlines a mechanistic trial to investigate the acute and 12-week cardiovascular, renal, and gastrointestinal effects of incretin-based therapies in patients with type 2 diabetes.
Smits et al. (2015) conducted an RCT in type 2 diabetes (n=60). Incretin-based therapies (exenatide, liraglutide, sitagliptin) vs. placebo was evaluated on Change in resting heart rate variability, glomerular filtration rate, pancreatic exocrine function, and faecal elastase-1 levels. This protocol outlines a randomized trial evaluating the cardiovascular, renal, and gastrointestinal effects of incretin-based therapies versus placebo in 60 patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: